Clinical trials: Controlled Hypertension
Pulmonary Arterial Hypertension
A Multinational, Multicenter, Study to Assess the Efficacy and Safety of BPS-314d-MR in Subjects With Pulmonary Arterial Hypertension Currently Receiving Treatment With an Endothelin Receptor Antagonist and/or a Phosphodiesterase-5 Inhibitor
A multinational, multicenter, double-blind, randomized, placebo-controlled, Phase III study to assess the efficacy and safety of BPS 314d-MR in subjects with pulmonary arterial hypertension currently receiving treatment with an…
- Trial name
- NCT01458236
- Testing
- Beraprost Sodium 314d Modified Release Tablets
- Sponsor
- Lung Biotechnology PBC
Essential Hypertension
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Response of Vasomera (PB1046) Injection Following a Single Subcutaneous Dose in Subjects With Stage 1 or 2 Essential Hypertension
The primary objective of the study is to evaluate the safety and tolerability of single ascending doses of Vasomera (PB1046) administered subcutaneously in adult subjects with Stage 1 or Stage 2 essential hypertension.
- Trial name
- NCT01523067
- Testing
- Vasomera (PB1046), 0.9% Sodium Chloride
- Where
- 5 sites in United States
- Volunteers
- 68 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Diabetes Mellitus, Type 2, Hypertension
Study of Safety and Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes And Hypertension (MK-8835-042)
MK-8835-042 (B1521004) is designed to assess the safety and efficacy of an investigational drug, ertugliflozin (MK-8835, PF-04971729), in participants with type 2 diabetes and hypertension.
- Trial name
- NCT01096667
- Testing
- Ertugliflozin 1 mg, Ertugliflozin 5 mg, Ertugliflozin 25 mg
- Volunteers
- 194 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension
Effectiveness of Valsartan/Amlodipine (EXforge®) and Nifedipine treAtment coMparison in Treating Chinese Hypertensive Patients
The purpose of this study was to compare the efficacy and safety of Valsartan/Amlodipine (EXforge®) with nifedipine, as well as vascular function index.
- Trial name
- EXAM (NCT01167153)
- Testing
- Valsartan/Amlodipine, Nifedipine
- Where
- China
- Volunteers
- 564 people
- Sponsor
- Novartis
Hypertension
A Study on the Long-term Efficacy of Nebivolol After Withdrawal of Therapy
This study will evaluate the long-term efficacy of nebivolol monotherapy in patients with stage 1 or stage 2 hypertension after the withdrawal of active medication.
- Trial name
- NCT00785512
- Testing
- Nebivolol
- Where
- 26 sites in United States
- Volunteers
- 207 people
- Sponsor
- Forest Laboratories
Pulmonary Arterial Hypertension
Clinical Study of Pulsed, Inhaled Nitric Oxide Versus Placebo in Symptomatic Subjects With PAH
Phase 3, placebo controlled, double-blind, randomized clinical study to determine safety, tolerability, and efficacy of pulsed, inhaled nitric oxide (iNO) versus placebo in symptomatic subjects with pulmonary arterial…
- Trial name
- INOvation-1 (NCT02725372)
- Testing
- Inhaled Nitric Oxide 75 mcg/kg IBW/hr
- Where
- 109 sites in United States, Australia and 16 more
- Volunteers
- 207 people
- Sponsor
- Bellerophon Pulse Technologies
Resistant Hypertension
A Study of CIN-107 in Adults With Treatment-Resistant Hypertension (rHTN)
This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of CIN-107 as compared to placebo after 12 weeks of treatment in patients with treatment-resistant…
- Trial name
- BrigHTN (NCT04519658)
- Testing
- CIN-107
- Where
- 80 sites in United States
- Volunteers
- 275 people
- Sponsor
- CinCor Pharma, Inc.
Pulmonary Arterial Hypertension
Efficacy and Safety Study of Udenafil in Patient With Pulmonary Arterial Hypertension(PAH)
This is a placebo-controlled, double-blind, phase II clinical study to evaluate the efficacy and safety of Udenafil in patient with Pulmonary Arterial Hypertension(PAH).
- Trial name
- NCT01553721
- Testing
- udenafil
- Where
- 9 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Dong-A ST Co., Ltd.
Essential Hypertension
Efficacy and Safety of Valsartan/Amlodipine in Patients With Mild to Moderate Essential Hypertension
This study assessed the efficacy and safety of the valsartan/amlodipine 160/5 mg single-pill combination in patients with uncomplicated essential hypertension not adequately controlled (MSDBP ≥90 mmHg and <110 mmHg) on valsartan…
- Trial name
- NCT01001572
- Testing
- Valsartan/amlodipine 160/5 mg, Valsartan 160 mg
- Volunteers
- 932 people
- Sponsor
- Novartis
Open-angle Glaucoma, Ocular Hypertension
Preservative-Free MK2452 (Tafluprost) for Open-Angle Glaucoma/Ocular Hypertension (MK2452-001)(COMPLETED)
This study was to compare the safety and efficacy of the preservative-free formulation of 0.0015% MK2452 (tafluprost) and preservative-free 0.5% timolol maleate in patients with open-angle glaucoma and ocular hypertension.
- Trial name
- NCT01026831
- Testing
- Preservative-Free Tafluprost, Comparator: timolol
- Volunteers
- 643 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Dyslipidemias
Clinical Trial to Evaluate the Efficacy and Safety of OLOMAX Tab
The purpose of this study is to evaluate the efficacy and safety of OLOMAX Tab (20/5/5mg, 20/5/10mg) in Hypertension Patients with Low-Intermediate Risk for Cardiovascular Disease.
- Trial name
- NCT04120753
- Testing
- OLOMAX 20/5/5mg, OLOMAX 20/5/10mg, Olmesartan 20 mg/Amlodipine 5 mg
- Where
- South Korea
- Volunteers
- 106 people
- Sponsor
- Daewoong Pharmaceutical Co. LTD.
Blood Pressure
Evaluation of Target Organs Impairment on Patients Suffering From High Blood Pressure
Evaluation of target organs impairment on patients suffering from high blood pressure without known cardio vascular or renal disease, stratified on blood pressure control.
- Trial name
- PREVENTA (NCT00925470)
- Where
- 369 sites in France
- Volunteers
- 1,200 people
- Sponsor
- AstraZeneca
Pulmonary Arterial Hypertension
Study of Cicletanine for Pulmonary Arterial Hypertension (PAH)
This Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study will compare the efficacy, safety, and tolerability of cicletanine hydrochloride (HCl) to placebo in subjects with PAH.
- Trial name
- NCT00832507
- Testing
- Cicletanine
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 162 people
- Sponsor
- Gilead Sciences
Hypertension
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
The purpose of this study is to evaluate of efficacy and safety of HCP1904-1 and RLD2001-1 alone in patients with essential hypertension inadequately controlled on RLD2001-1 monotherapy.
- Trial name
- NCT04820907
- Testing
- HCP1904-1, RLD2001-1
- Where
- South Korea
- Volunteers
- 123 people
- Sponsor
- Hanmi Pharmaceutical Company Limited
Hypertension
Efficacy and Safety of Azilsartan Medoxomil, Once Daily (QD), Co-Administered With Amlodipine in Participants With Essential Hypertension
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil, once daily (QD), co-administered with amlodipine in treating individuals with essential hypertension, compared to treatment with amlodipine…
- Trial name
- NCT00591266
- Testing
- Azilsartan Medoxomil and amlodipine, Amlodipine
- Where
- 50 sites in United States
- Volunteers
- 566 people
- Sponsor
- Takeda
Pulmonary Arterial Hypertension
Single and Multiple Ascending Doses Clinical Pharmacology Study With KAR5585
Safety, tolerability, pharmacokinetics (PK), cardiac conduction and food effect study on single and multiple ascending doses of KAR5585 in healthy adults.
- Trial name
- NCT02746237
- Testing
- KAR5585 Capsules
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Karos Pharmaceuticals
Open Angle Glaucoma, Ocular Hypertension
Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure
To evaluate the ocular hypotensive efficacy of PG324 ophthalmic solution relative to its individual components in patients with open angle glaucoma or ocular hypertension.
- Trial name
- NCT02057575
- Testing
- PG324 Ophthalmic Solution 0.01%, PG324 Ophthalmic Solution 0.02%, Netarsudil (AR-13324) Ophthalmic Solution 0.02%
- Where
- 23 sites in United States
- Volunteers
- 298 people
- Sponsor
- Aerie Pharmaceuticals
Hypertension
A Study of VCT220 in Participants With Hypertension and Obesity or Overweight
The purpose of this study is to explore the safety and efficacy of VCT220 for the treatment of hypertension in participants with obesity or overweight.
- Trial name
- VICTOR-HTN (NCT07360275)
- Testing
- VCT220 Tablet
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Vincentage Pharma Co., Ltd
Hypertension
Evaluation of the Safety, Efficacy and Pharmacokinetics of MICARDIS® (Telmisartan) in Children and Adolescents With Hypertension
Study to assess the blood pressure lowering effects of two doses of telmisartan over a four-week treatment period; to determine potentially effective doses for pediatric patients for future studies; to assess the safety and…
- Trial name
- NCT02242344
- Testing
- Telmisartan
- Volunteers
- 77 people
- Sponsor
- Boehringer Ingelheim
Hypertension, Diabetic Nephropathy
Antiproteinuric Effect of Valsartan and Lisinopril
Title: Antiproteinuric effect of valsartan, lisinopril and valsartan versus lisinopril in non-diabetic and diabetic renal disease: a randomized (3:3:1), double blind, parallel group, controlled trial, 5 months follow-up.
- Trial name
- NCT00171574
- Testing
- Valsartan, Valsartan plus HCTZ, Lisinopril
- Where
- Switzerland
- Volunteers
- 124 people
- Sponsor
- Novartis